OKYO
Okyo Pharma·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
MACD Golden Cross
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OKYO
Okyo Pharma Limited
A company that developing therapeutics to treat inflammatory eye diseases and ocular pain
Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB
--
Okyo Pharma Limited is incorporated in Guernsey. They are a preclinical biopharmaceutical company developing next-generation therapies to improve the lives of patients with inflammatory eye disease and eye pain. Their research program focuses on a new G protein-coupled receptor (GPCR). Their therapeutic approach focuses on targeting the inflammatory and pain-regulating pathways that drive these diseases. They are currently developing OK-101, their main preclinical product candidate for the treatment of dry eye. They also plan to evaluate its benefits in patients with ocular nerve pain, uveitis and allergic conjunctivitis. They have also been evaluating OK-201, a bovine adrenal medulla, or BAM, a lipid peptide preclinical analog candidate for the treatment of neuropathic eye pain, and plan to maintain this drug candidate at an exploratory level while focusing the company's main efforts on the OK-101 project.
Company Financials
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
